Skip to main content

INDV 6-K

Indivior Pharmaceuticals, Inc. (INDV)

6-K 2024-12-26 For: 2024-12-26
View Original
Added on April 10, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

________________________

Washington, D.C. 20549

_____________________

FORM 6-K

_____________________

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of December 2024

Commission File Number: 001-37835

________________________________________

Indivior PLC

________________________________________

10710 Midlothian Turnpike, Suite 125

North Chesterfield, Virginia 23235

(Address of principal executive office)

_______________________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit No. Description of Exhibit
99.1 Announcement sent to the London Stock Exchange on December 24,<br>2024, titled “Transaction in Own<br>Shares”.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Indivior PLC
Date: December 24, 2024 /s/<br>Kathryn Hudson
Name:<br>Kathryn Hudson
Title:<br>Company Secretary

a1753r2

Exhibit 99.1

INDIVIOR PLC

SHARE REPURCHASE PROGRAM

WEEKLY REPORT

December 24, 2024

INDIVIOR PLC ("Indivior") announces that it purchased for cancellation a total of 209,246 of its ordinary shares of $0.50 each through Morgan Stanley & Co. International Plc in the period from December 16, 2024, up to and including December 20, 2024, in connection with its $100m Share Repurchase Program. Aggregated information on the purchase of these shares can be found in the table below.

Following the purchase and cancellation of the above shares (including those purchased but not yet settled), Indivior has 125,062,916 ordinary shares of $0.50 each with voting rights in issue. There are no shares held in treasury.

The above figure (125,062,916) may be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, Indivior under the FCA's Disclosure Guidance and Transparency Rules.

All repurchases by Indivior are "On Exchange" transactions (as such term is defined in the rules of the London Stock Exchange) and "on market" for the purposes of the Companies Act 2006.

Aggregated information

Trading<br>Date Trading<br>Venue Aggregated<br>daily volume (number of shares) Daily<br>weighted average purchase price of the shares (p)
16/12/2024 LSE 16,243 920.78
16/12/2024 BATE 6,034 919.89
16/12/2024 CHIX 16,371 919.54
16/12/2024 AQUIS 3,123 916.77
17/12/2024 LSE 25,718 931.58
17/12/2024 BATE 5,231 931.09
17/12/2024 CHIX 16,759 930.15
17/12/2024 AQUIS 821 926.66
18/12/2024 LSE 14,770 942.76
18/12/2024 BATE 6,911 941.62
18/12/2024 CHIX 15,222 942.22
18/12/2024 AQUIS 2,465 942.17
19/12/2024 LSE 16,217 910.35
19/12/2024 BATE 4,669 908.69
19/12/2024 CHIX 16,156 911.69
19/12/2024 AQUIS 1,697 912.18
20/12/2024 LSE 16,317 912.01
20/12/2024 BATE 6,705 908.38
20/12/2024 CHIX 14,161 908.16
20/12/2024 AQUIS 3,656 918.09

Transaction details

In accordance with Article 5(1)(b) of the assimilated Market Abuse Regulation (EU) No 596/2014, as it forms part of Retained EU Law as defined in the European Union (Withdrawal) Act 2018 and Commission Delegated Regulation (EU) 2016/1052, a full breakdown of the individual purchases of ordinary shares made by Morgan Stanley & Co. International Plc on behalf of Indivior during the above period as part of the Share Repurchase Program can be found at www.indivior.com/en/investors/shareholder-information/share-repurchase-program.

Indivior PLC's Legal Entity Identifier code is 213800V3NCQTY7IED471.

Contact:

Jason Thompson

Vice President, Investor Relations

1-804-402-7123